Overview

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.
Phase:
Phase 2
Details
Lead Sponsor:
Edison Pharmaceuticals Inc
PTC Therapeutics
Treatments:
Ubiquinone